Clinical outcomes of extracorporeal membrane oxygenation support in patients with hematologic malignancies.
10.3904/kjim.2015.30.4.478
- Author:
Hye Seon KANG
1
;
Chin Kook RHEE
;
Hea Yon LEE
;
Young Kyoon KIM
;
Soon Seog KWON
;
Seok Chan KIM
;
Jong Wook LEE
Author Information
1. Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Extracorporeal membrane oxygenation;
Hematologic neoplasms;
Adults;
Mortality;
Complications
- MeSH:
APACHE;
Adult;
Aged;
*Extracorporeal Membrane Oxygenation/adverse effects/mortality;
Female;
Hematologic Neoplasms/diagnosis/mortality/*therapy;
Hospital Mortality;
Humans;
Kaplan-Meier Estimate;
Male;
Medical Records;
Middle Aged;
Predictive Value of Tests;
Republic of Korea;
Retrospective Studies;
Risk Assessment;
Risk Factors;
Time Factors;
Treatment Outcome
- From:The Korean Journal of Internal Medicine
2015;30(4):478-488
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND/AIMS: The clinical outcomes of patients with hematologic malignancies who were treated with extracorporeal membrane oxygenation (ECMO) after the failu re of optimal conventional therapy were determined. METHODS: The medical records of all patients administered ECMO during their stay in a medical intensive care unit of Seoul St. Mary's Hospital between February 2010 and July 2013 were reviewed retrospectively. RESULTS: In total, 15 patients with hematologic malignancies were compared to 33 immunocompetent patients with documented cardiorespiratory failure. Underlying hematologic malignancies were significantly associated with lower overall survival (0.0% vs. 24.2%, p = 0.044). Mortality was significantly associated with a higher 24 hours ECMO inspired fraction of oxygen (0.71 +/- 0.24 vs. 0.47 +/- 0.13, p = 0.015), the development of infection after ECMO (87.5% vs. 25.0%, p = 0.001), and the presence of hyperbilirubinemia (70.0% vs. 0.0%, p < 0.001). Matching of the patients based on their Acute Physiology and Chronic Health Evaluation II scores confirmed the greater risk of mortality in patients with hematologic malignancies (survival: 0.0% vs. 40.0%, p = 0.017). The mean difference in inotropic-equivalent scores after ECMO was significantly lower in the immunocompetent patients than in those with hematologic malignancies (-59.22 +/- 97.83 vs. 53.87 +/- 164.46, p = 0.026). CONCLUSIONS: Patients with hematologic malignancies who require ECMO for respiratory support have poor outcomes. The incidence of complications in these patients did not significantly differ from that in immunocompetent patients.
